Diclofenac, a selective COX-2 inhibitor, inhibits DMH-induced colon tumorigenesis through suppression of MCP-1, MIP-1α and VEGF

Molecular Carcinogenesis

Volumn 50, Issue 9, 2011, Pages 707-718

  Kaur, Jasmeet ^a   Sanyal, S N ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

1,2 dimethylhydrazine; Colon cancer; MCP 1; MIP 1 ; MMP 9; VEGF

Indexed keywords

1,2 DIMETHYLHYDRAZINE; CHEMOKINE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; GELATIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CHEMOPROPHYLAXIS; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; ZYMOGRAPHY;

1,2-DIMETHYLHYDRAZINE; ANIMALS; BLOTTING, WESTERN; CARCINOGENS; CHEMOKINE CCL2; CHEMOKINE CCL3; COLONIC NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; DICLOFENAC; IMMUNOHISTOCHEMISTRY; MALE; RATS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

RATTUS;

EID: 79960642638     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20736     Document Type: Article

References (47)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
2. Mitchell RN, Cotran RS. Hemodynamic disorders, thrombosis, and shock. In: Cotran RS, editor. Pathologic basis of disease. 6th edition. Philadelphia: WB Saunders Co; 1999. pp. 113-138.
3. Cotran RS, Kumar V, Collins T. Acute and chronic inflammation. In: Cotran RS, editor. Pathologic basis of disease. 6th edition. Philadelphia: WB Saunders Co.; 1999. pp. 50-88.
4. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
5. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
6. Gimbrone M, Leapman S, Cotrans R, Folkman J. Tumor dormancy in vitro by prevention of neovascularization. J Exp Med 1972; 136: 261-276.
7. O'Connor DS, Schechner JS, Adida C, et al. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 2000; 156: 393-398.
8. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med 2003; 9: 677-684.
9. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumor-cell plasticity: Lessons from melanoma. Nat Rev Cancer 2003; 3: 411-421.
10. Bernardini G, Ribatti D, Spinetti G, et al. Analysis of the role of chemokines in angiogenesis. J Immunol Methods 2002; 273: 83-101.
11. Rollins BJ. Chemokines. Blood 1997; 90: 909-928.
12. Brown KD, Zurawski SM, Mossmann TR, Zurwski C. A family of small inducible proteins secreted by leukocytes is members of a new superfamily that include leukocyte and fibroblast-derived inflammatory agents, growth factors and indicators of various activation processes. J Immunol 1989; 142: 679-687.
13. Ohta M, Kitadai Y, Tanaka S, et al. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas. Int J Oncol 2003; 22: 773-778.
14. Timmers HT, Pronk GJ, Bos JL, van-der-Eb AJ. Analysis of the rat JE gene promoter identifies an AP-1 binding site essential for basal expression but not for TPA induction. Nucleic Acids Res 1990; 18: 23-34.
15. Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K. Properties of the novel pro-inflammatory supergene 'intercrine' cytokine family. Annu Rev Immunol 1991; 9: 617-648.
16. Koide N, Nishio A, Sato T, Sugiyama A, Miyagawa S. Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus. Am J Gastroenterol 2004; 99: 1667-1674.
17. Cheadle EJ, Riyad K, Subar D, et al. Eotaxin-2 and colorectal cancer: A potential target for immune therapy. Clin Cancer Res 2007; 13: 5719-5728.
18. 2 pathway to inhibit apoptosis in early stages of colon carcinogenesis and its chemoprevention by diclofenac. Tumor Biol 2010; 31: 623-631.
19. Kaur J, Sanyal SN. Modulation of inflammatory changes in early stages of colon cancer through activation of PPARγ by diclofenac. Eur J Cancer Prev 2010; 19: 319-327.
20. Kaur J, Sanyal SN. Intrinsic mitochondrial membrane potential change and associated events mediate apoptosis in chemopreventive effect of diclofenac in colon cancer. Oncol Res 2010; 18: 481-492.
21. Kaur J, Sanyal SN. Alterations in membrane fluidity and dynamics during initial stages of colon carcinogenesis and its chemoprevention by diclofenac. Mol Cell Biochem 2010; 341: 99-108.
22. Kaur J, Sanyal SN. Induction of apoptosis as potential chemopreventive effect of dual cyclooxygenase inhibitor, diclofenac in early colon carcinogenesis. J Environ Pathol Toxicol Oncol 2010; 29: 41-53.
23. Kaur J, Sanyal SN. Oxidative stress and stress-signaling in chemoprevention of early colon cancer by diclofenac. Am J Biomed Sci 2010; 2: 63-78.
24. Kaur J, Sanyal SN. Association of PI3-kinase and Wnt signaling in non-steroidal anti-inflammatory drug-induced apoptosis in experimental colon cancer. Am J Biomed Sci 2009; 1: 395-405.
25. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
26. Billings PC, Habres JM, Liao DC, Tuttle SW. Human fibroblasts contain a proteolytic activity which is inhibited by the Bowman-Birk protease inhibitor. Cancer Res 1991; 51: 5539-5543.
27. Brittan M, Wright NA. Stem cell in gastrointestinal structure and neoplastic development. Gut 2004; 53: 899-910.
28. van Leeuwen IMM, Edwards CM, Ilyas M, Byrne HM. Towards a multiscale model of colorectal cancer. World J Gastroenterol 2007; 13: 1399-1407.
29. Sengottuvelan M, Senthilkumar R, Nalini N. Modulatory influence of dietary resveratrol during different phases of 1, 2-dimethylhydrazine induced mucosal lipid-peroxidation, antioxidant status and aberrant crypt foci development in rat colon carcinogenesis. Biochim Biophys Acta 2006; 1760: 1175-1183.
30. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells over-expressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501.
31. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-716.
32. Janakiram NB, Rao CV. Role of lipoxins and resolvins as anti-inflammatory and proresolving mediators in colon cancer. Curr Mol Med 2009; 9: 565-579.
33. Hanahan D, Folkman J. Patterns and emerging mechanism of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
34. Furuya M, Nishiyama M, Kimura S, et al. Expression of regulator of G protein signaling protein 5 (RGS5) in the tumor vasculature of human renal cell carcinoma. J Pathol 2004; 203: 551-558.
35. 2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA 2004; 101: 591-596.
36. Melyyk O, Shuman MA, Kim KJ. Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res 1996; 56: 921-924.
37. Matrisan LM. Metalloproteinases and their inhibitors in matrix remodelling. Trends Genet 1990; 6: 121-125.
38. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 2000; 18: 1135-1149.
39. Zeng ZS, Huang Y, Cohen AM, Guillem JG. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 1996; 14: 3133-3140.
40. Tsujii M, Kawano S, Dubois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94: 3336-3340.
41. Ogawa M, Yamamoto H, Nagano H, et al. Hepatic expression of Ang-2 RNA in metastatic colorectal cancer. Hepatology 2004; 39: 528-539.
42. Yoshidome H, Kohno H, Shida T, et al. Significance of monocyte chemoattractant protein-1 in angiogenesis and survival in colorectal liver metastases. Int J Oncol 2009; 34: 923-930.
43. Tanaka S, Tatsuguchi A, Futagami S, et al. Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma. Gut 2006; 55: 54-61.
44. Nakashima E, Mukaida N, Kubota Y, et al. Human MCAF gene transfer enhances the metastatic capacity of a mouse cachectic adenocarcinoma cell line in vivo. Pharm Res 1995; 12: 1598-1604.
45. Muta M, Matsumoto G, Nakashima E, Toi M. Mechanical analysis of tumor growth regression by the cyclooxygenase-2 inhibitor, DFU, in a walker 256 rat tumor model: Importance of monocyte chemoattractant protein-1 modulation. Clin Cancer Res 2006; 12: 264-272.
46. Nakashima E, Oya A, Kubota Y, et al. A candidate for cancer gene therapy: MIP-1α gene transfer to an adenocarcinoma cell line reduced tumorigenicity and induced protective immunity in immunocompetent mice. Pharm Res 1996; 13: 1896-1901.
47. Cho M, Gwaka J, Parka S, et al. Diclofenac attenuates Wnt/β-catenin signaling in colon cancer cells by activation of NF-κB. FEBS Lett 2005; 579: 4213-4218.